Patent ID: 7338955

Claim:
A method for a chemotherapeutic treatment of a neuropathy characterized by administration to a patient suffering from neuropathy, from 1-100 mg/day of a pharmaceutical agent comprising a compound of formula (I): in which R 1 =C 1-6 alkyl, optionally substituted with halogen, R 2 =hydrogen or C 1-4 alkyl, optionally substituted with halogen or replaced with halogen, R 3 =C 2-4 alkyl, optionally substituted with halogen, R 4 =SO 2 NR 5 R 6 , C 1-4 alkyl, optionally substituted with NR 5 R 6 , CN, CONR 5 R 6 , CO 2 R 7 , or halogen, C 2-4 -alkenyl, optionally substituted with NR 5 R 6 , SONR 5 R 6 , CONR 5 R 6 , CO 2 R 7 , or halogen, C 2-4 -alkanoyl, optionally substituted with NR 5 R 6 , SONR 5 R 6 , CONR 5 R 6 , CO 2 R 7 , or halogen, R 5 and R 6 , independent of one another, represent hydrogen or C 1-4 alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR 8 )-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C 1-4 alkyl groups, R 7 =hydrogen or C 1-4 alkyl, optionally, substituted with fluorine, and R 8 =hydrogen, C 1-3 alkyl, or hydroxy alkyl having 1-4 C atoms, or a pharmaceutically acceptable salt thereof, wherein the neuropathy is selected from the group consisting of a peripheral diabetic polyneuropathy, gastroparesis, a toxic neuropathy, and a metabolic neuropathy.